Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
CMS proposes Medicare reimbursement — AOTI benefits from topical wound oxygen therapy
The US agency CMS has published a draft that would deem topical oxygen therapy medically necessary for diabetic foot ulcers after four weeks of non‑healing and provide for nationwide Medicare reimbursement. The draft enters a 45‑day comment period; a final decision is expected within a year. AOTI reports a 75% market share in this segment, expects an addressable market potential of up to $26 billion with reimbursement, and cites a near‑term revenue potential of around $400 million with existing payer coverage. » Mere på de.investing.com
Virksomhedstal
| (EUR) | december 2025 | YoY |
|---|---|---|
| Omsætning | 29,06 mio. | - |
| Bruttofortjeneste | 16,23 mio. | - |
| Nettoresultat | 2,03 mio. | - |
| EBITDA | 3,81 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 178,82 mio. € |
Antal aktier | 106,36 mio. |
Højeste/laveste i 52 uger | 1,80 € - 0,30 € |
| Udbytte | Nej |
Beta | 2,88 |
P/E (PE Ratio) | 74,28 |
PEG (PEG Ratio) | 0,74 |
K/I (PB Ratio) | 9,40 |
P/S (PS Ratio) | 2,90 |
Virksomhedsprofil
| Navn | AOTI INC |
| CEO | Michael Griffiths |
| Medarbejdere | 90 |
Deep Dive
Tickersymboler
| Børs | Symbol |
|---|---|
London | AOTI.L |